Publication: Benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients
2
Issued Date
2013-10-16
Resource Type
ISSN
18768172
Other identifier(s)
2-s2.0-84885362320
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Open Breast Cancer Journal. Vol.5, No.1 (2013), 7-15
Suggested Citation
Sagita Dewi, Stig Larsen, Vichien Srimuninnimit, Yen Shen Lu, Tjakra Manuaba, Steen Lindkær-Jensen Benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients. Open Breast Cancer Journal. Vol.5, No.1 (2013), 7-15. doi:10.2174/1876817220130613001 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/31189
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in the treatment of stage IV breast cancer patients
Abstract
An anti-cancer agent containing benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) was developed to establish a low toxic and cost effective treatment of breast cancer. The study was aimed to investigate if BP-C1 could be given continuously without rest periods and to estimate Maximum Tolerated (MTD) and Minimum Efficient Dose (MED) in metastatic breast cancer (MBC) treatment. A non-randomized, multicentre trial with 3-level Response Surface Pathway design was performed. Five MBC patients were included at each of the three design levels. BP-C1 was daily administrated intramuscularly during 32 days. The first five patients were given a cumulative dose of 0.64 mg/kg bodyweight. Based on the obtained results, the dose was increased /decreased for the next five patients in the next design level. The main variable was the National Cancer Institute Common Toxicity Criteria (NCI-CTC). Cumulative doses of 0.96 mg/kg or higher were defined as high-dose. One moderate and one mild increase in maximum NCI-CTC were found on 0.64 mg/kg, one mild increase occurred on 0.96 mg/kg and no changes were detected on 1.12 mg/kg. The Sum NCI-CTC increased (p=0.07) in the low-dose group, but reduced (p=0.09) in the high-dose group. In the high-dose group, 62.5% of the patients were classified as responders including one complete responder compared to 28.6% in the low-dose group. In conclusion, BP-C1 can safely be administrated continuously during 32 days. The MTD is larger than 1.12 mg/kg and MED estimated to 0.96 mg/kg. © Dewi et al.; Licensee Bentham Open.